Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparlisib plus paclitaxel vs placebo plus paclitaxel in recurrent or metastatic head and neck squamous cell carcinoma
2013-000744-26Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Buparlisib plus paclitaxel with Placebo plus paclitaxel (2 arms). Primary endpoint: Progression Free Survival. Started Jun 2013; status: terminated.
02
Drugs
buparlisib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2013-000744-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000744-26.